Sign up Australia
Proactive Investors - Run By Investors For Investors

Q BioMed's pipeline boosted as tech partner gets funding for glaucoma therapeutic research

Partner Mannin Research Inc has received funding to carry out a proof of concept study for the treatment
Q BioMed's pipeline boosted as tech partner gets funding for glaucoma therapeutic research
The eyes have it...Mannin is researching a new therapeutic for glaucoma

Biotech accelerator firm Q BioMed Inc (OTCMKTS:QBIO) announced further progress in its bid to expand its pipeline.

Partner Mannin Research Inc has received funding to carry out a proof of concept study for a new therapeutic for eye condition  glaucoma, in which the optic nerve is damaged.

The R&D funding comes from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) and the number of potential patients demanding better treatments make this a multi-billion-dollar opportunity, says QBiomed.

The company has licensed the Mannin Tie2 technology, and is collaboratively developing the Tie2 platform for glaucoma, and other indications.

It has the potential to treat several additional, vascular related diseases, such as acute kidney injury, and cardiorenal syndrome.

"As our understanding about the Angiopoietin-Tie2 system grows, I am very excited about the clinical therapeutic possibilities," said Dr. Sarah Quaggin from Mannin.

The new biologic would be an additional product to the Mannin Tie2 pipeline.

Meanwhile,  Q BioMed said development of the MAN-01 small molecule for the treatment of primary open-angle glaucoma continues on-pace and is now at a point where the most active candidates will be selected for final testing and optimization as a soluble, topical eye drop that permeates well into the eye.

It is anticipated that pre-clinical IND enabling studies will begin in the second quarter of 2018.

Shares in New York eased 0.27% to US$3.69.

View full QBIO profile View Profile

Q BioMed Inc Timeline

Related Articles

Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
picture of addict
November 16 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
Frosties Box
December 05 2017
The company is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use